Literature DB >> 30686804

Poor Quality of Warfarin Treatment Increases the Risk of All Types of Intracranial Hemorrhage in Atrial Fibrillation.

Paula Tiili1, Jukka Putaala2, Juha Mehtälä3, Houssem Khanfir3, Jussi Niiranen1, Pasi Korhonen3, Pekka Raatikainen1, Mika Lehto1.   

Abstract

BACKGROUND: Intracranial hemorrhage (ICH) is a devastating complication of oral anticoagulation. The aim of this study was to describe the spectrum of ICH and to evaluate the association of warfarin control with the risk of ICH in a nationwide cohort of unselected atrial fibrillation (AF) patients. Methods and 
Results: The FinWAF is a retrospective registry-linkage study. Data were collected from several nationwide Finnish health-care registers and laboratory databases. The primary outcome was any ICH (traumatic or non-traumatic). The quality of warfarin therapy was assessed continuously by calculating the time in therapeutic range in a 60-day window (TTR60). Adjusted Cox proportional hazard models were used. A total of 53,953 patients were included (53% men; mean age, 73 years; mean follow-up, 2.94 years; mean TTR, 63%). In 129,684 patient-years, 1,196 patients had ICH (non-traumatic, 53.5%; traumatic, 43.6%; traumatic subdural, 38.6%); crude annual rate, 0.92%; 95% CI: 0.87-0.98). A lower TTR60 was significantly associated with higher risk of ICH (TTR60 ≤40% vs. TTR60 >80%; adjusted hazard ratio, 2.16; 95% CI: 1.83-2.54). Other variables independently associated with ICH included age >65 years, previous stroke, male sex, low hemoglobin, thrombocytopenia, elevated alanine aminotransferase, and previous bleeding other than ICH.
CONCLUSIONS: Poor control of warfarin treatment was associated with elevated risk of ICH. Approximately half of the ICH were traumatic, mainly subdural.

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Intracranial hemorrhage; Warfarin

Mesh:

Substances:

Year:  2019        PMID: 30686804     DOI: 10.1253/circj.CJ-18-0975

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  3 in total

1.  Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine.

Authors:  Rubén Ángel Martín-Sánchez; Noel Lorenzo-Villalba; Alberto Elpidio Calvo-Elías; Ester Emilia Dubón-Peralta; Cynthia Elisa Chocrón-Benbunan; Carmen María Cano-de Luque; Lidia López-García; María Rivas-Molinero; Cristina Outón-González; Javier Marco-Martínez; Elpidio Calvo-Manuel; Emmanuel Andres; Manuel Méndez-Bailón
Journal:  Medicina (Kaunas)       Date:  2021-04-09       Impact factor: 2.430

Review 2.  Anemia and iron deficiency in patients with atrial fibrillation.

Authors:  Nicole Hanna-Rivero; Samuel J Tu; Adrian D Elliott; Bradley M Pitman; Celine Gallagher; Dennis H Lau; Prashanthan Sanders; Christopher X Wong
Journal:  BMC Cardiovasc Disord       Date:  2022-05-04       Impact factor: 2.174

3.  Physician-Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development.

Authors:  Na Wang; Sha Qiu; Ya Yang; Chi Zhang; Zhi-Chun Gu; Yan Qian
Journal:  Front Pharmacol       Date:  2021-06-09       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.